JPMorgan Chase & Co. Analysts Give Gerresheimer (ETR:GXI) a €92.10 Price Target


Share on StockTwits

Gerresheimer (ETR:GXI) has been assigned a €92.10 ($108.35) price target by equities researchers at JPMorgan Chase & Co. in a report released on Thursday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 6.29% from the stock’s previous close.

A number of other research firms have also recently issued reports on GXI. Independent Research set a €85.00 ($100.00) target price on Gerresheimer and gave the company a “sell” rating in a research note on Friday, February 19th. DZ Bank restated a “buy” rating on shares of Gerresheimer in a report on Tuesday, March 30th. The Goldman Sachs Group set a €111.00 ($130.59) target price on Gerresheimer and gave the stock a “buy” rating in a report on Monday, March 22nd. Kepler Capital Markets set a €88.00 ($103.53) price target on Gerresheimer and gave the stock a “sell” rating in a research report on Wednesday, December 9th. Finally, Deutsche Bank Aktiengesellschaft set a €112.00 ($131.76) price target on Gerresheimer and gave the stock a “buy” rating in a research report on Friday, February 19th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of €101.30 ($119.18).

Shares of Gerresheimer stock opened at €86.65 ($101.94) on Thursday. Gerresheimer has a 12 month low of €61.70 ($72.59) and a 12 month high of €103.70 ($122.00). The company has a quick ratio of 0.61, a current ratio of 0.95 and a debt-to-equity ratio of 116.19. The stock has a market cap of $2.72 billion and a PE ratio of 30.73. The business has a fifty day simple moving average of €85.86 and a 200 day simple moving average of €90.64.

Gerresheimer Company Profile

Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass, plastic products, and drug delivery-devices and solutions primarily worldwide. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables, and components for dialysis machines, and catheters and surgical devices.

Recommended Story: What type of investment options does a Roth IRA provide?

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.